Profile Picture Deirdre Pratt

created Sep 27 2021

updated Feb 18 2022

Description

CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection and refers to the prevalence of the population with both anti-S and anti-N antibodies.
This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence

Activity
Community Rating
Current value: 0 out of 5
Your Rating
Current value: 0 out of 5
Raters
0
Visits
1294
Downloads
809
Comments
0
Contributors
0
Meta
Category
Laboratory Surveillance
Permissions
Public
Tags
covid, covid-19, covid19, coronavirus, laboratory, prevalence, sars-cov, seroprevalence, serosurveys
Row Label
Prevalence Estimate
SODA2 Only
Yes
Licensing and Attribution
Data Provided By
National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases
Source Link
https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html
License
Public Domain U.S. Government
Common Core
Contact Name
Surveillance Review and Response Group
Contact Email
eocevent394@cdc.gov
Publisher
CDC
Public Access Level
public
Issued
2021-10-01
Bureau Code
009:20
Program Code
009:020
Geographic Coverage
US
Temporal Applicability
2020-07-01/2021-12-14
Update Frequency
Monthly
Data Quality
Footnotes
Blank fields in the dataset represent insufficient sampling. Therefore, rates could not be calculated.
This view cannot be displayed